Yuxiang Long

Yuxiang Long

Auto-generated profile, based on publicly available information

Yuxiang Long

Department of Cardiovascular Medicine, The Second Affiliated Hospital of Chongqing Medical University, China (Y. Long, Y. Lai, Y.R., X.M., D.L., L.C., X.L., T.X., Z. Liu, Z. Ling, Y.C., H.Z., Y.Y.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
XHXinyu Hu
Xinyu Hu
DLDan Li
Dan Li
WCWeijie Chen
Weijie Chen
HKHongyu Kuang
Hongyu Kuang
DYDan Yang
Dan Yang
YYYuehui Yin
Yuehui Yin
Background: Heart failure with preserved ejection fraction (HFpEF) is a multifaceted syndrome with high morbidity and mortality. Empagliflozin, an SGLT2 (sodium–glucose cotransporter 2) inhibitor, reduces adverse events in patients with HFpEF regardless of glycemic control. However, the precise cardioprotective mechanisms of SGLT2 inhibitor in HFpEF remain underexplored. Methods and Results: A “2‐hit” mouse model of HFpEF was developed via the high‐fat diet combined with N ω ‐nitro‐L‐arginine methyl ester. Male C57BL/6N mice were assigned to either a control group (n=10) or an HFpEF group (n=20), with the latter receiving empagliflozin (10 mg/kg per day, n=10) or vehicle (n=10) for 8 weeks. Cardiac function, hypertrophy, and fibrosis were evaluated by physiological, biochemical, and histological measurements. Mechanistic analysis, including RNA sequencing, Western blotting, and immunohistochemistry, was conducted. In vitro, H9c2 cardiomyocytes were exposed to angiotensin II and palmitate, followed by empagliflozin treatment. In vivo, empagliflozin treatment improved body weight, blood pressure, glucose tolerance, and reduced cardiac hypertrophy, fibrosis, and diastolic dysfunction in HFpEF mice. Mechanistic analysis revealed that empagliflozin modulated the AMPK (AMP‐activated protein kinase)/mTORC1 (mammalian target of rapamycin complex 1)/autophagy signaling pathway. Specifically, empagliflozin restored the autophagy markers (Beclin1 and LC3‐II [microtubule‐associated protein 1 light chain 3]) and altered the phosphorylation of AMPK, mTOR, and p70S6K (ribosomal protein S6 kinase beta‐1). Inhibition of AMPK or autophagy nullified the antihypertrophic effect of empagliflozin, underscoring the dependence on the AMPK/mTORC1/autophagy pathway. Conclusions: Empagliflozin effectively ameliorates cardiac remodeling and diastolic dysfunction in HFpEF by enhancing autophagy via the AMPK/mTORC1 pathway. These findings elucidate the direct cardioprotective mechanisms of empagliflozin and suggest potential therapeutic molecular targets for HFpEF.

4 November 2020 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
YLYu-Xiang Long
Yu-Xiang Long
ZLZengzhang Liu
Zengzhang Liu
Background. Transcatheter aortic valve replacement (TAVR), widely used as an alternative therapy in patients with severe aortic stenosis, is expected to be offered to low-risk patents with a longer life expectancy. The durability of transcatheter aortic valve is becoming of increasing importance. Method. PubMed, Embase, and Cochrane CENTRAL from the inception to March 2020 were systematically screened for studies reporting on structural valve deterioration (SVD) in TAVR patients. Incidence of SVD was diagnosed according to the latest European consensus as the primary end point. Predictors of SVD evaluated at multivariable analysis and cumulative incidence function (CIF) of SVD were the secondary end point. Result. Twelve studies encompassing 10031 patients evaluating the incidence of SVD were included, with a follow-up between 1 and 8 years. The pooled incidence of SVD was 4.93% (95% CI, 2.75%-7.70%, I-2 = 96%) at 1 year and 8.97% (95% CI, 6.89%-11.29%, I-2 = 86%) in the long term (>= 5 years). Subgroup analysis was performed to identify the valve type that may result in partial heterogeneity. SVD was more frequent in patents with a valve diameter of 5 years), occurring more commonly in renal dysfunction patients, with small valve diameter and without OAC exposure. There may be an underestimation of the incidence if we assume death as a competing risk.

1 July 2026 in Hypertension
Verified
Journal Article
Open access
YLYuxiang Long
Yuxiang Long
YLYinchuan Lai
Yinchuan Lai
YRYiwen Ren
Yiwen Ren
XMXiaomin Ma
Xiaomin Ma
DLDan Li
Dan Li
YYYuehui Yin
Yuehui Yin
BACKGROUND: The aorticorenal ganglion (ARG), an upstream component of renal sympathetic fibers, may represent a novel target for autonomic modulation in hypertension. This study evaluated the effects of adjunctive ARG ablation after renal denervation (RDN) on blood pressure (BP) and its autonomic mechanisms. METHODS: Patients with uncontrolled hypertension scheduled for RDN were enrolled, and additional ablation was performed if an elevation in SBP was observed by high-frequency stimulation at the ARG region (RDN+ARG ablation). This exploratory analysis assessed the change in 24-hour average ambulatory systolic BP from baseline to 3 months. To explore the effects of ARG ablation on BP and sympathetic activity, we compared ARG ablation with RDN in a canine model. RESULTS: A total of 41 patients (n=20 RDN; n=21 RDN+ARG ablation) were enrolled. At 3 months, the reduction in 24-hour average ambulatory systolic BP from baseline was −9.7±10.8 mm Hg in the RDN group and −18.2±10.8 mm Hg in the RDN+ARG ablation group, with a between-group difference of −7.5 mm Hg (95% CI, −13.9 to −1.2 mm Hg; P =0.021) after adjusting for baseline ambulatory systolic BP. No major procedure-related complications were observed in both groups. In canines, ARG ablation significantly reduced the renal sympathetic innervation and the systemic sympathetic activity compared with RDN, with enhancing SBP-lowering effect. CONCLUSIONS: These results establish the ARG as a pivotal regulator of systemic sympathetic tone and a promising therapeutic target for hypertension. Additional ARG ablation to RDN may represent a more effective interventional strategy, warranting validation in large-scale clinical trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05590871.